Max Sauter

List of Publications by Citations

Source: https://exaly.com/author-pdf/9563961/max-sauter-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24 201 8 13 g-index

29 269 ext. papers ext. citations 5.4 avg, IF L-index

| # | Paper | IF | Citations |
|----|---|--------------------|-----------|
| 24 | Radiolabeling strategies for tumor-targeting proteinaceous drugs. <i>Molecules</i> , 2014 , 19, 2135-65 | 4.8 | 36 |
| 23 | Identification of a Novel ITGE inding Peptide Using Protein Separation and Phage Display. <i>Clinical Cancer Research</i> , 2017 , 23, 4170-4180 | 12.9 | 29 |
| 22 | Comparison of the RGD Motif-Containing Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1679-1685 | 8.9 | 26 |
| 21 | Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. <i>International Journal of Pharmaceutics</i> , 2016 , 512, 87-95 | 6.5 | 23 |
| 20 | Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. <i>Journal of Controlled Release</i> , 2020 , 322, 200-208 | 11.7 | 16 |
| 19 | PET/CT Imaging of NSCLC with a Integrin-Targeting Peptide. <i>Molecular Imaging and Biology</i> , 2019 , 21, 973-983 | 3.8 | 13 |
| 18 | High treatment efficacy by dual targeting of Burkitt <mark>u lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i>, 2016, 43, 489-98</mark> | 8.8 | 11 |
| 17 | Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. <i>Bioanalysis</i> , 2019 , 11, 1459-1467 | 2.1 | 8 |
| 16 | An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 174, 633-638 | 3.5 | 6 |
| 15 | An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. <i>Bioanalysis</i> , 2019 , 11, 887-898 | 2.1 | 6 |
| 14 | Preclinical evaluation of peptide-based radiotracers for integrin MB-positive pancreatic carcinoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2019 , 58, 309-318 | 1.8 | 3 |
| 13 | Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. <i>Journal of Pharmaceutical Analysis</i> , 2020 , 10, 233-239 | 14 | 3 |
| 12 | Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. <i>Analytica Chimica Acta</i> , 2020 , 1114, 42-49 | 6.6 | 3 |
| 11 | Overcoming the Mucosal Barrier: Tetraether Lipid-Stabilized Liposomal Nanocarriers Decorated with Cell-Penetrating Peptides Enable Oral Delivery of Vancomycin. <i>Advanced Therapeutics</i> , 2021 , 4, 20 | 0 0 247 | 3 |
| 10 | Reporter cell assay-based functional quantification of TNF-Eantagonists in serum - a proof-of-principle study for adalimumab. <i>Analytical Biochemistry</i> , 2020 , 596, 113646 | 3.1 | 2 |
| 9 | Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 186, 113276 | 3.5 | 2 |
| 8 | Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. <i>Cancer Letters</i> , 2016 , 381, 296-304 | 9.9 | 2 |

LIST OF PUBLICATIONS

| 7 | Development and Validation of an LC-MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. <i>ACS Omega</i> , 2020 , 5, 24329-24 | 1339 | 2 |
|---|---|-------------------|---|
| 6 | New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2020 , 109, 2090-2094 | 3.9 | 2 |
| 5 | Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1176, 122781 | 3.2 | 1 |
| 4 | Rapid and Sensitive Quantification of Intracellular Glycyl-Sarcosine for Semi-High-Throughput Screening for Inhibitors of PEPT-1. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 1 |
| 3 | Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides - Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 194, 11372 | 3.5 2 8 | 1 |
| 2 | Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. <i>Analytical and Bioanalytical Chemistry</i> , 2021 , 413, 5645-5654 | 4.4 | О |
| 1 | LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. <i>Neuro-Oncology</i> , 2022 , 24, i93-i93 | 1 | |